The priority intervention is naloxone, given as soon as opioid toxicity is suspected in a patient who is not breathing adequately — but in respiratory arrest, naloxone is given alongside, not instead of, opening the airway and providing ventilation. The American Heart Association's 2020 guideline update and the 2023 American College of Medical Toxicology position statement both frame it this way: naloxone reverses the cause while rescue breathing and, if needed, high-quality CPR keep oxygen moving until the drug takes effect. Neither alone is sufficient, and the order of operations matters when the patient has no pulse.

That distinction is where most quick answers fall short. Naloxone is not a substitute for ventilation, and ventilation is not a substitute for naloxone. A patient in true respiratory arrest — no effective breathing, pulse may or may not be present — needs both within the same minute of recognition. What follows walks through the sequence, the doses, the traps, and the cases where the suspected opioid turns out to be something else.

Naloxone Takes Priority Because It Reverses the Cause, Not Just the Sign

Naloxone is a competitive opioid receptor antagonist. It displaces opioids from mu receptors in the brainstem, where opioid-induced respiratory depression is generated, and restores the drive to breathe. That is why it outranks every other drug intervention in suspected opioid toxicity: it targets the mechanism rather than supporting the patient around it. According to the 2020 AHA guideline update on opioid-associated emergencies, naloxone administration is reasonable for patients with suspected opioid-associated cardiac or respiratory arrest in the out-of-hospital setting, and it can be given by lay rescuers trained in it.

The dose for an adult in respiratory arrest is typically 2 mg intranasal or 0.4 mg intramuscular or intravenous, repeated every 2 to 3 minutes if breathing does not return. The 2023 American College of Medical Toxicology position statement on naloxone supports escalating doses and notes that higher doses may be needed for high-potency synthetic opioids such as illicitly manufactured fentanyl analogues and nitazenes. Repeat dosing is not a sign of failure; it reflects variable receptor occupancy and drug potency.

A common mistake is treating naloxone as a one-shot fix. Someone gives 2 mg intranasally, sees no response after 30 seconds, and concludes the patient isn't opioid-toxic. That reasoning is wrong on two counts: nasal absorption is slower and less reliable in a patient with no circulation, and the opioid may be more potent than the dose can outcompete. The correct move is to continue ventilation and repeat the dose, not to abandon the diagnosis.

Keep the route in mind too. Intranasal delivery is the default for lay rescuers because it requires no needle, but the AHA and the American Heart Association's first aid guidance both note that intramuscular or intravenous routes work faster when a trained provider has access. In a true arrest, an IV or IO route is preferred if it's already available, because absorption from the nose depends on mucosal blood flow that may be compromised. Titrate to breathing, not to full consciousness — a patient who wakes up agitated and vomiting is at risk of aspiration and immediate withdrawal.

Open the Airway and Ventilate While the Naloxone Is Being Prepared

Respiratory arrest means the patient is not moving enough air to sustain life. Naloxone takes 2 to 5 minutes to work by the intranasal route and 1 to 2 minutes by the intramuscular route, depending on the product and the patient's circulation. That gap is why airway and breathing support starts first in practice, even though naloxone is the priority drug. A brain deprived of oxygen for four minutes begins to suffer irreversible injury; a brain waiting two minutes for naloxone has a much better chance.

The sequence taught in basic life support and echoed in AHA opioid-emergency guidance is: check responsiveness and breathing, call for help and naloxone, open the airway, give rescue breaths, and give naloxone as soon as it's available. For a suspected opioid overdose with a pulse, rescue breathing at roughly one breath every 5 to 6 seconds — about 10 to 12 breaths per minute — is the standard. For a patient with no pulse, standard CPR with compressions and ventilations applies.

Ventilation is not optional padding around the drug. Opioid-induced respiratory arrest kills through hypoxia, and hypoxia is what you're correcting in real time while the antagonist works. A bag-valve-mask with supplemental oxygen is ideal for trained responders; a pocket mask or barrier device is the layperson's version. If you have neither, the AHA's guidance for lay rescuers still favors rescue breaths over nothing, though compression-only CPR is recommended when a rescuer is unwilling or unable to give breaths.

Positioning matters more than most people think. A patient who is slumped forward with a occluded airway won't benefit from either naloxone or rescue breaths until the head is tilted and the chin lifted, or the jaw is thrust. If you suspect a spinal injury or the patient is in a confined space, jaw thrust is the safer maneuver. Once breathing returns, place the patient in the recovery position on their side to reduce aspiration risk, and keep monitoring — naloxone's effect can wear off before the opioid does.

If There Is No Pulse, CPR Outranks Everything Else

Here's the boundary that changes the answer: if the patient has no pulse, the priority becomes high-quality CPR, and naloxone is given as an adjunct during resuscitation, not as the thing you stop compressions to find. The AHA's 2020 guideline update is explicit that standard resuscitation — compressions, ventilations, defibrillation if indicated — is the framework, with naloxone layered in for suspected opioid-associated arrest. Chest compressions circulate whatever oxygen remains; nothing else does that job.

In practice this means the rescuer starts compressions, and a second rescuer prepares and administers naloxone without interrupting the compression cycle. The 2020 AHA update notes that naloxone can be given during CPR and that rescuers should not delay compressions to give it. If the arrest is witnessed and opioid toxicity is strongly suspected, some protocols allow naloxone to be given before or during the first cycle, but the compressions never stop for it.

A specific failure case worth knowing: a patient found unresponsive with pinpoint pupils and no breathing may have a pulse that's too slow and weak to feel. Lay rescuers are taught to check for breathing and a pulse for no more than 10 seconds; if unsure, start CPR. The AHA's guidance for opioid emergencies acknowledges that lay rescuers may struggle to distinguish respiratory arrest with a pulse from cardiac arrest, and it errs toward starting compressions when uncertain, because compressions on a patient with a pulse are far less harmful than missing a cardiac arrest.

There's a regional wrinkle. Some European resuscitation councils and the UK's Resuscitation Council publish opioid-specific algorithms that place naloxone earlier in the sequence for presumed opioid arrest than US guidance does, particularly in the prehospital setting where a provider can give IV naloxone within seconds. The underlying logic is the same; the sequencing reflects who is available to give the drug and how fast. If you're training to a specific jurisdiction's protocol, follow that protocol — the AHA and European Resuscitation Council documents are the authorities to check.

The Exact Sequence to Follow, Step by Step

Here's the working order for a suspected opioid respiratory arrest, drawn from AHA basic life support and opioid-emergency guidance. It assumes an adult or adolescent; pediatric dosing differs and follows weight-based naloxone protocols.

1: Check responsiveness and breathing for no more than 10 seconds. Shout, tap, and look for chest rise. Pinpoint pupils and slow, shallow breathing raise suspicion but are not required. 2: Call emergency services and send someone for naloxone and an AED. Give the address, say "suspected opioid overdose, not breathing," and stay on the line. 3: Open the airway with head-tilt chin-lift or jaw thrust, and give two rescue breaths if not breathing normally. 4: Give naloxone as soon as it's in hand: 2 mg intranasal in one nostril, or 0.4 mg IM/IV if trained. Continue rescue breaths at 10 to 12 per minute. 5: Check for a pulse. If absent or uncertain, start CPR immediately and continue naloxone as an adjunct. 6: Repeat naloxone every 2 to 3 minutes if breathing hasn't returned, up to the protocol's limit, while continuing ventilation. 7: Once breathing returns, place the patient in the recovery position, monitor continuously, and hand off to EMS with the dose and time of naloxone given.

If naloxone isn't available or the patient doesn't respond after repeated doses, keep ventilating and keep the airway open until EMS arrives — ventilation alone can sustain a patient through opioid-induced respiratory depression. If the patient responds but becomes combative or vomits, protect the airway and don't restrain them face-down; sudden return of consciousness after naloxone can be disorienting, and positional asphyxia is a documented risk in that window. If you suspect a mixed overdose — opioids plus benzodiazepines or alcohol — naloxone won't reverse the sedative component, so ventilation and monitoring remain essential.

Suspected Opioid Toxicity Is Not the Same as Confirmed Opioid Toxicity

The word "suspected" carries weight. Naloxone is safe in opioid-naive patients and in patients whose altered mental status turns out to have another cause, which is why the AHA and ACMT both support giving it on suspicion rather than waiting for confirmation. But suspicion should be grounded in the toxidrome: depressed consciousness, slow or absent breathing, and pinpoint pupils, often with track marks, drug paraphernalia nearby, or a witness account.

The classic pitfall is anchoring on opioids when the real cause is hypoglycemia, head injury, or a sedative-hypnotic overdose. Naloxone won't fix those, and time spent repeating doses is time not spent checking a glucose level or protecting the airway. The ACMT's 2023 statement is clear that naloxone should not delay other resuscitative care, and that a patient who doesn't respond to adequate doses should prompt reconsideration of the diagnosis rather than an assumption that the opioid was simply too strong.

Pinpoint pupils are supportive but not decisive. They can occur with pontine hemorrhage, organophosphate poisoning, and some sedatives, and they can be absent in opioid overdose if the patient also took a stimulant or has anoxic brain injury. Conversely, a patient with normal pupils and slow breathing can still be opioid-toxic. Treat the breathing and the suspected cause; let the pupils inform, not dictate.

The practical rule: give naloxone on suspicion, keep ventilating, and reassess the whole picture. If breathing improves dramatically after naloxone, the diagnosis is supported. If it doesn't improve after two or three appropriate doses with good ventilation, broaden the differential and tell EMS what you've given and when. Documenting the dose and time is not paperwork for its own sake — it changes what the receiving team does next.

Intranasal Versus Injectable Naloxone: Which Form Wins in an Arrest

Both forms save lives, and the choice depends on who is giving the drug and what's available. The table below compares them on the dimensions that matter in a respiratory arrest.

Feature Intranasal naloxone IM/IV naloxone
Typical adult arrest dose 2 mg per dose (some products 4 mg) 0.4 mg per dose
Time to effect Roughly 2–5 minutes Roughly 1–2 minutes IV; 2–5 minutes IM
Training required Minimal; lay-rescuer friendly Injection technique; IV access for IV route
Reliability in low circulation Reduced nasal absorption IV/IO preferred; IM absorption also slows in shock
Repeat dosing Every 2–3 minutes Every 2–3 minutes
Main drawback Slower onset; product-specific device Needle handling; access delays in the field

Intranasal wins for bystanders and first responders without IV access. It requires no needle, no sharps disposal, and minimal training, which is why community naloxone distribution programs and most public-access kits use it. The FDA has approved several intranasal products, including a 4 mg and a 3 mg device, and the AHA's guidance supports intranasal use by trained lay rescuers.

Injectable wins when a provider already has access. IV naloxone works fastest when a line is in place, and IO access is the fallback in arrest. IM is the middle option — faster than intranasal in a patient with decent circulation, slower in shock. The ACMT notes that in severe acidosis and poor perfusion, neither nasal nor IM absorption is dependable, which pushes providers toward IV or IO when they can get it.

The verdict is conditional, not absolute: for a layperson with a kit, intranasal is the right pick; for a paramedic or nurse with access, IV or IO is preferred in arrest, with IM as a bridge. One genuine drawback of intranasal that's rarely stated plainly: a bloody or obstructed nose, or a patient in profound shock, can cut absorption enough that the dose effectively fails, and the rescuer may wrongly conclude the patient isn't opioid-toxic. If intranasal doesn't work and you have injectable naloxone available, switch routes.

Doses, Repeat Intervals, and the Trap of Titrating to Wakefulness

The standard adult arrest doses are 2 mg intranasal or 0.4 mg IM/IV, repeated every 2 to 3 minutes as needed. The goal is restoration of adequate breathing, not full alertness. That distinction is in the AHA's opioid guidance and in the ACMT statement, and it matters because over-reversal causes agitation, vomiting, and withdrawal, while under-reversal leaves the patient hypoventilating.

Higher doses are sometimes needed. The ACMT's 2023 position statement addresses the rise of high-potency synthetic opioids and supports escalating doses when the initial dose is inadequate, with the caveat that the evidence base for specific high-dose regimens is still maturing. In practice, many EMS protocols allow repeated 2 mg intranasal doses up to 4 to 8 mg total before considering alternative diagnoses or routes. The exact ceiling is protocol-specific — check your local EMS or state naloxone protocol, because these vary by jurisdiction.

Repeat intervals are not arbitrary. Naloxone's duration of action is roughly 30 to 90 minutes, shorter than many opioids, especially long-acting ones like methadone and extended-release formulations. That means a patient who wakes up after one dose can relapse into respiratory depression before EMS arrives or before the receiving hospital can observe them. The AHA and ACMT both emphasize monitoring for re-sedation and repeat dosing if breathing deteriorates.

Titrating to wakefulness is the trap. A patient who is breathing adequately but drowsy does not need more naloxone. A patient who is awake but agitated and vomiting may need less. The target is a respiratory rate and oxygen saturation that sustain life, and the way to get there is to give the dose, watch the breathing, and support the airway in the meantime. If you're unsure whether the patient is breathing adequately, keep ventilating and reassess — the ventilator is doing the work the drug hasn't done yet.

What Changes for Children, Pregnancy, and Long-Acting Opioids

Pediatric dosing is weight-based, and the arrest sequence differs in emphasis. The AHA's pediatric guidance supports naloxone at 0.1 mg/kg IV/IM/IO for children, with intranasal dosing adjusted by product concentration, and it emphasizes that ventilation and CPR follow pediatric basic life support ratios. A child in respiratory arrest from suspected opioid toxicity still gets airway and breathing support first in practice, with naloxone as soon as it's available.

Pregnancy adds a layer. Opioid overdose in pregnancy threatens both mother and fetus, and maternal resuscitation is fetal resuscitation — restoring the mother's breathing and circulation is the priority. The AHA and obstetric guidance support naloxone in pregnancy for suspected opioid toxicity; the drug does not appear to cause fetal harm at standard doses, and untreated maternal hypoxia is far more dangerous. After resuscitation, the patient needs obstetric evaluation regardless of how well she looks.

Long-acting opioids are the case that breaks the one-dose assumption. Methadone's duration can exceed naloxone's by hours, and extended-release formulations and high-potency synthetics can outlast a single dose. The ACMT position statement notes that patients exposed to long-acting opioids may need repeated naloxone dosing or a continuous infusion, and that observation for at least several hours after reversal is standard. A patient who wakes up and refuses transport after one dose of naloxone is a re-arrest waiting to happen.

The through-line for all three groups is the same: the priority doesn't change, but the dose, the monitoring window, and the handoff do. Children need weight-based dosing and pediatric CPR ratios; pregnant patients need maternal-first resuscitation and obstetric follow-up; long-acting opioid exposures need longer observation. None of these is a reason to delay naloxone or ventilation — they're reasons to plan the next hour, not just the next minute.

FAQ

Can naloxone be given before rescue breaths if it's the only thing available?

Yes. If you have naloxone in hand and no barrier device, giving it first is reasonable, then open the airway and give breaths as soon as you can. The AHA's lay-rescuer guidance supports naloxone administration by trained bystanders without waiting for equipment, but ventilation remains essential because naloxone takes 1 to 5 minutes to work and the brain needs oxygen now. The sequence that saves the most lives is naloxone and ventilation together, not one instead of the other.

What if the patient doesn't respond to naloxone at all?

Reconsider the diagnosis after two or three appropriate doses with good ventilation. According to the 2023 American College of Medical Toxicology position statement, a non-response should prompt evaluation for other causes — hypoglycemia, head injury, sedative-hypnotic overdose, or anoxic injury — rather than repeated dosing without end. Keep ventilating and get the patient to emergency care. Document the total dose and timing so the receiving team knows what's already been tried.

Is intranasal or injectable naloxone faster in an arrest?

Injectable, specifically IV or IO, is faster when access is available — roughly 1 to 2 minutes versus 2 to 5 minutes for intranasal. But speed of access matters too: a bystander with an intranasal kit can give it in 20 seconds, while waiting for a trained provider to start an IV costs minutes. For lay rescuers, intranasal is the practical choice; for providers with access, IV or IO is preferred in arrest, with IM as a bridge.

How long does naloxone last compared with the opioid?

Naloxone's effect lasts roughly 30 to 90 minutes, which is shorter than methadone, extended-release opioids, and many high-potency synthetics. That mismatch is why re-sedation is a real risk and why the AHA and ACMT both call for monitoring after reversal. A patient who wakes up and leaves against advice after one dose can stop breathing again before the opioid wears off; observation for several hours is standard for long-acting exposures.

Can a layperson give naloxone without training?

Most public-access intranasal products are designed for use with minimal or no prior training, and the AHA supports naloxone administration by lay rescuers trained in it. Reading the device instructions at the moment of need is not ideal, which is why community programs teach the steps in advance. If you carry naloxone, know the device, the dose, and the repeat interval before you need it — that preparation is what turns a kit into an intervention.

Does naloxone work for overdoses involving fentanyl or nitazenes?

It can, but higher or repeated doses are often needed. The ACMT's 2023 statement addresses the rise of high-potency synthetic opioids and supports escalating doses when the initial dose is inadequate, while noting the evidence base for specific high-dose regimens is still developing. The principle is to keep ventilating and repeat the dose every 2 to 3 minutes rather than assuming naloxone can't work. If breathing doesn't return despite adequate dosing and ventilation, treat it as a possible mixed overdose and get advanced care.

Should I put the patient in the recovery position after naloxone?

Yes, once breathing returns. The recovery position — on the side, head tilted back slightly — reduces aspiration risk if the patient vomits, which is common as consciousness returns. Keep monitoring breathing continuously, because naloxone can wear off before the opioid does. Don't leave the patient alone, and don't restrain them face-down if they become agitated; positional asphyxia is a documented risk in that window.

This article is general educational information about emergency response and is not a diagnosis, treatment plan, or substitute for training and local protocol. Naloxone dosing and resuscitation sequences vary by jurisdiction and by patient age and condition; follow your local EMS or public health protocol and consult a qualified clinician for individual medical decisions. If you or someone else is in immediate danger, call your local emergency number or a crisis line right away.